 Vanessa Fabrizio
Concepts (55)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2023 | 280 | 1.810 |
Why?
| | Immunotherapy, Adoptive | 9 | 2024 | 297 | 1.510 |
Why?
| | Receptors, Antigen, T-Cell | 9 | 2024 | 703 | 1.280 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2022 | 574 | 1.010 |
Why?
| | Burkitt Lymphoma | 2 | 2023 | 56 | 0.920 |
Why?
| | Graft vs Host Disease | 2 | 2020 | 237 | 0.710 |
Why?
| | Cytomegalovirus | 1 | 2021 | 153 | 0.670 |
Why?
| | Cytomegalovirus Infections | 1 | 2021 | 187 | 0.620 |
Why?
| | Bone Marrow Transplantation | 1 | 2018 | 268 | 0.550 |
Why?
| | Bone Marrow | 1 | 2018 | 268 | 0.540 |
Why?
| | Graft Survival | 1 | 2018 | 505 | 0.500 |
Why?
| | Recurrence | 4 | 2023 | 1003 | 0.390 |
Why?
| | Retrospective Studies | 13 | 2025 | 14571 | 0.380 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 75 | 0.380 |
Why?
| | T-Lymphocytes | 5 | 2024 | 1924 | 0.380 |
Why?
| | Child | 16 | 2025 | 20806 | 0.370 |
Why?
| | Neoplasms | 2 | 2021 | 2475 | 0.280 |
Why?
| | Antigens, CD19 | 3 | 2022 | 115 | 0.270 |
Why?
| | Infant | 6 | 2025 | 8993 | 0.260 |
Why?
| | Young Adult | 8 | 2023 | 12389 | 0.240 |
Why?
| | Neuronal Ceroid-Lipofuscinoses | 1 | 2025 | 4 | 0.240 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2025 | 99 | 0.220 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 28 | 0.210 |
Why?
| | Vidarabine | 1 | 2022 | 30 | 0.200 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 64 | 0.180 |
Why?
| | Child, Preschool | 5 | 2025 | 10451 | 0.180 |
Why?
| | Adolescent | 8 | 2025 | 20302 | 0.170 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2021 | 168 | 0.170 |
Why?
| | Humans | 17 | 2025 | 129128 | 0.170 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 174 | 0.160 |
Why?
| | Antigens, CD34 | 1 | 2018 | 89 | 0.150 |
Why?
| | Cognition Disorders | 1 | 2022 | 497 | 0.150 |
Why?
| | Transplantation, Homologous | 1 | 2018 | 396 | 0.140 |
Why?
| | Genomics | 1 | 2021 | 716 | 0.130 |
Why?
| | Hematopoietic Stem Cells | 1 | 2018 | 378 | 0.120 |
Why?
| | Blood Platelets | 1 | 2018 | 375 | 0.120 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2021 | 1048 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 963 | 0.110 |
Why?
| | Neutrophils | 1 | 2018 | 1195 | 0.100 |
Why?
| | Chronic Disease | 3 | 2023 | 1707 | 0.100 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3033 | 0.090 |
Why?
| | Prospective Studies | 1 | 2022 | 7079 | 0.080 |
Why?
| | Adult | 5 | 2024 | 35513 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2021 | 10227 | 0.070 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2025 | 50 | 0.060 |
Why?
| | Administration, Intravenous | 1 | 2023 | 137 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2023 | 385 | 0.050 |
Why?
| | Male | 4 | 2025 | 63202 | 0.050 |
Why?
| | Female | 4 | 2025 | 68518 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2025 | 862 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 622 | 0.040 |
Why?
| | Cost of Illness | 1 | 2021 | 289 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2022 | 1004 | 0.040 |
Why?
| | United States | 2 | 2023 | 13940 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2021 | 5739 | 0.020 |
Why?
|
|
Fabrizio's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|